Skip to main content

ACADVL KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 1.

Be the first to review this product! Submit a review

Images

Western blot - Human ACADVL (VLCAD) knockout HEK-293T cell lysate (AB257332), expandable thumbnail
  • Sanger Sequencing - Human ACADVL (VLCAD) knockout HEK-293T cell lysate (AB257332), expandable thumbnail

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Knockout validation

Sanger Sequencing, Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 1.

Alternative names

ACAD 6, ACADV_HUMAN, Acadvl, Acyl CoA dehydrogenase very long chain, Acyl Coenzyme A dehydrogenase very long chain, LCACD, VLCAD, Very long chain specific acyl CoA dehydrogenase mitochondrial, Very long-chain specific acyl-CoA dehydrogenase, mitochondrial

What's included?

1 Kit
Components
Human ACADVL knockout HEK293T cell lysate
1 x 100 µg
Human wild-type HEK293T cell lysate
1 x 100 µg

Recommended products

ACADVL KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 1.

Key facts

Cell type

HEK-293T

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 1.

Concentration
Loading...

Properties

Gene name

ACADVL

Gene editing type

Knockout

Gene editing method

CRISPR technology

Knockout validation

Sanger Sequencing, Western blot

Zygosity

Homozygous

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Storage

Shipped at conditions

Ambient - Can Ship with Ice

Appropriate short-term storage conditions

-20°C

Appropriate long-term storage conditions

-20°C

Notes


Knockout cell lysate achieved by CRISPR/Cas9.

Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

ACADVL also known as VLCAD (Very Long-Chain Acyl-CoA Dehydrogenase) is an enzyme that plays an important role in the breakdown of long-chain fatty acids within the mitochondria. It has a molecular mass of approximately 70 kDa. VLCAD is expressed in various tissues with high levels found in the heart skeletal muscle and liver. These tissues are heavily reliant on fatty acid oxidation for energy production especially when glucose availability is low.

Biological function summary

ACADVL functions within the mitochondrial matrix where it catalyzes the initial step of beta-oxidation by desaturating long-chain acyl-CoA molecules. This enzyme is a part of a larger complex that includes other mitochondrial dehydrogenases contributing to the degradation of fatty acids into acetyl-CoA units. The process is essential for energy production especially under fasting conditions or high-energy demand scenarios such as muscle contraction and cardiac function.

Pathways

VLCAD plays an essential role in the fatty acid beta-oxidation pathway. It works alongside other enzymes such as ACADM (Medium-Chain Acyl-CoA Dehydrogenase) to facilitate the sequential shortening of fatty acids which integrates into the Krebs cycle for further energy extraction. This pathway maximizes energy yield from fatty acids significantly influencing cellular metabolism and energy homeostasis.

Associated diseases and disorders

VLCAD deficiencies lead to severe metabolic conditions such as VLCAD deficiency. This disorder results in the impaired breakdown of long-chain fatty acids causing energy deficiency and the accumulation of toxic substances. Symptoms range from muscle weakness to serious cardiac complications. VLCAD deficiency's impact is often assessed in relation to proteins like ACSL1 and CPT2 which are involved in the fatty acid metabolism pathway and are central to effective energy processing in cells.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

2 product images

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com